COVID-19 rapid test

for antigensSARS-COV-2nasopharyngeal

The LumiraDx SARS-CoV-2 Ag Pool Test is a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to 5 individuals suspected of COVID-19 or up to 5 asymptomatic individuals. Used with the LumiraDx Platform the test offers a rapid, scalable and cost-effective screening solution for infectious individuals. Test benefits Quickly and easily scale up testing: Low-cost diagnostic screening solutions Maximize resources: Pooled testing can improve access to testing by significantly reducing resources (tests, operators, instruments) required on a per patient basis Save Time: Pooled testing can result in a 40-60% reduction in testing, allowing for significant savings in both time and cost High sensitivity of up to Ct 33 enables the accurate detection of the majority of infectious patients Easy to implement in point of care settings Room Temperature test strip storage Compact and portable instrument with connectivity options Facilitate reopening of work sites, sports, cultural venues and events and travel Regular testing of defined populations e.g. healthcare staff, healthcare facility residents, employees, students One time testing of groups for pre entry or reopening of sites Test workflow The Instrument and Test Strips are integrated with several quality control checks to ensure the Instrument and Test are functioning correctly for every test run. The workflow process is comprised of a simple sample prep along with step-by-step guidance of the Instrument to report a patient result in under 12 minutes from sample application.